Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay

American Journal of Clinical Pathology

Volumn 134, Issue 2, 2010, Pages 303-311

  Huang, Weidong ^a   Reinholz, Monica ^b   Weidler, Jodi ^a   Lie, Yolanda ^a   Paquet, Agnes ^a   Whitcomb, Jeannette ^a   Lingle, Wilma ^b   Jenkins, Robert B ^b   Chen, Beiyun ^b   Larson, Jeffrey S ^a   Tan, Yuping ^a   Sherwood, Thomas ^a   Bates, Michael ^a   Perez, Edith A ^c  

^a Monogram Biosciences ^*  (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Breast cancer; Central HER2 testing; Concordance; HER2 homodimers; Polysomy 17; Quantitative total HER2 expression

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE; HER2 HOMODIMER; PARAFFIN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ARTICLE; BIOASSAY; BREAST CANCER; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

BREAST NEOPLASMS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS;

EID: 77955597966     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP3BZY4YAFNTRG     Document Type: Article

References (33)

1. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712. (Pubitemid 19147683)
2. Dendukuri N, Khetani K, McIsaac M, et al. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ. 2007;176:1429-1434. (Pubitemid 46762020)
3. Hamilton A, Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER2, p53 and BCL-2. Ann Oncol. 2000;11:647-663.
4. Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90:1346-1360.
5. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst. 2000;92:1991-1998. (Pubitemid 32045895)
6. Konecny GE, Thomssen C, Luck HJ, et al. HER2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst. 2004;96:1141-1151. (Pubitemid 39207050)
7. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792. (Pubitemid 32222155)
8. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726. (Pubitemid 34111379)
9. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684. (Pubitemid 41464706)
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672. (Pubitemid 41464705)
11. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809-820. (Pubitemid 43290919)
12. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29-36.
13. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
14. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing: National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94:852-854. (Pubitemid 34705057)
15. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the Breast Intergroup Trial N9831. J Natl Cancer Inst. 2002;94:855-857.
16. Reinholz MM, Jenkins RB, Hillman D, et al. The clinical significance of polysomy 17 in the HER2+ N9831 Intergroup Adjuvant Trastuzumab Trial [abstract]. Breast Cancer Res Treat. 2007;106:S11. Abstract 36.
17. Dowsett M, Procter M, McCaskill-Stevens W, et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol. 2009;27:2962-2969.
18. Shi Y, Huang W, Tan Y, et al. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. Diagn Mol Pathol. 2009;18:11-21.
19. Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002;77:148-154.
20. Cell Markers and Cytogenetics Committees College of American Pathologists. Clinical laboratory assays for HER2/ neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med. 2002;126:803-808.
21. Mascarello JT, Brothman AR, Davison K, et al. Proficiency testing for laboratories performing fluorescence in situ hybridization with chromosome-specific DNA probes. Arch Pathol Lab Med. 2002;126:1458-1462. (Pubitemid 36237250)
22. Westgard JO, Barry PL, Hunt MR, et al. A multi-rule Shewhart chart for quality control in clinical chemistry. Clin Chem. 1981;27:493-501.
23. Downs-Kelly E, Yoder BJ, Stoler M, et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol. 2005;29:1221-1227. (Pubitemid 41232996)
24. Pauletti G, Godolphin W, Press MF, et al. Detection and quantitation of HER2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13:63-72. (Pubitemid 26248546)
25. Reinholz MM, Bruzek AK, Visscher DW, et al. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol. 2009;10:267-277.
26. Hyun CL, Lee HE, Kim KS, et al. The effect of chromosome 17 polysomy on HER2/neu status in breast cancer. J Clin Pathol. 2008;61:317-321. (Pubitemid 351354237)
27. Vanden Bempt I, Van Loo P, Drijkoningen M, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER2 testing. J Clin Oncol. 2008;26:4869-4874.
28. Bose S, Mohammed M, Shintaku P, et al. HER2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/HER2/neu polysomy. Breast J. 2001;7:337-344. (Pubitemid 33101639)
29. Lal P, Salazar PA, Ladanyi M, et al. Impact of polysomy 17 on HER2/neu immunohistochemistry in breast carcinomas without HER2/neu gene amplification. J Mol Diagn. 2003;5:155-159. (Pubitemid 36974726)
30. Rosenberg CL. Polysomy 17 and HER2 amplification: true, true, and unrelated [editorial]. J Clin Oncol. 2008;26:4856-4858.
31. Toi M, Sperinde J, Huang W, et al. Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer. BMC Cancer. 2010;10:56. doi:10.1186/1471-2407-10-56.
32. Desmedt C, Sperinde J, Piette F, et al. Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. Diagn Mol Pathol. 2009;18:22-29.
33. Lipton A, Ali S, Leitzel K, et al. HER2 protein expression and homodimer levels predict response to trastuzumab in centrally tested FISH-positive metastatic breast cancer patients. Presented at the 31st CTRC-AACR San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. Abstract 550749.